Michael D.  Dale net worth and biography

Michael Dale Biography and Net Worth

CEO of AxoGen

A distinguished healthcare leader, Michael Dale currently serves as President, Chief Executive Officer and member of the Board of Directors for Axogen, Inc. (NASDAQ: AXGN), a global leader dedicated to the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.

As an accomplished medical device executive, Mr. Dale has over 35 years of experience leading transformative, high-technology medical device companies in the cardiovascular, neuromodulation, diabetes and electrophysiology markets. His past executive leadership roles span both public and private medical device companies, including Abbott Structural Heart, GI Dynamics, Helical Solutions, ATS Medical, Endocardial Solutions, Cyberonics, St. Jude Medical and American Edwards Laboratories.

Mr. Dale has been an active director and advisor, serving on the boards of Preceptis Medical, Enpath Medical, Rhythmia Medical, Neuronetics, Inc., NeoChord, the Advanced Medical Technology Association (AdvaMed), the St. Mary’s University Council of Regents for the School of Graduate and Professional Programs, and the University of Minnesota Carlson School of Management Medical Industry Leadership Institute. At present, he serves on the advisory board of Purdue University’s Weldon School of Biomedical Engineering, and California Polytechnic State University’s Center for Innovation & Entrepreneurship as Student Mentor.

Mr. Dale holds a Bachelor of Science degree from California Polytechnic State University in San Luis Obispo, California.

What is Michael D. Dale's net worth?

The estimated net worth of Michael D. Dale is at least $3.10 million as of December 9th, 2025. Dale owns 88,537 shares of AxoGen stock worth more than $3,099,680 as of February 3rd. This net worth evaluation does not reflect any other assets that Dale may own. Learn More about Michael D. Dale's net worth.

How do I contact Michael D. Dale?

The corporate mailing address for Dale and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at [email protected]. Learn More on Michael D. Dale's contact information.

Has Michael D. Dale been buying or selling shares of AxoGen?

Michael D. Dale has not been actively trading shares of AxoGen during the last ninety days. Most recently, Michael D. Dale sold 61,463 shares of the business's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $31.21, for a transaction totalling $1,918,260.23. Following the completion of the sale, the chief executive officer now directly owns 88,537 shares of the company's stock, valued at $2,763,239.77. Learn More on Michael D. Dale's trading history.

Who are AxoGen's active insiders?

AxoGen's insider roster includes Marc Began (EVP), P Burke (Director), Michael Dale (CEO), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Lindsey Hartley (CFO), John Johnson (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Paul Thomas (Director), Joseph Tyndall (Director), Kathy Weiler (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.

Are insiders buying or selling shares of AxoGen?

In the last twelve months, insiders at the medical equipment provider sold shares 27 times. They sold a total of 475,453 shares worth more than $12,603,234.48. The most recent insider tranaction occured on December, 16th when Director Amy Mcbride Wendell sold 43,684 shares worth more than $1,280,378.04. Insiders at AxoGen own 2.8% of the company. Learn More about insider trades at AxoGen.

Information on this page was last updated on 12/16/2025.

Michael D. Dale Insider Trading History at AxoGen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2025Sell61,463$31.21$1,918,260.2388,537View SEC Filing Icon  
See Full Table

Michael D. Dale Buying and Selling Activity at AxoGen

This chart shows Michael D Dale's buying and selling at AxoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AxoGen Company Overview

AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $35.01
Low: $34.21
High: $35.93

50 Day Range

MA: $31.65
Low: $27.69
High: $35.02

2 Week Range

Now: $35.01
Low: $9.22
High: $36.00

Volume

499,774 shs

Average Volume

1,040,263 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1